{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,13]],"date-time":"2026-10-13T08:51:02Z","timestamp":1791881462661,"version":"4.3.4"},"reference-count":35,"publisher":"Elsevier BV","issue":"4","license":[{"start":{"date-parts":[[2026,4,1]],"date-time":"2026-04-01T00:00:00Z","timestamp":1775001600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,4,1]],"date-time":"2026-04-01T00:00:00Z","timestamp":1775001600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,12,10]],"date-time":"2025-12-10T00:00:00Z","timestamp":1765324800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/100005294","name":"Massachusetts General Hospital","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100005294","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","jaad.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of the American Academy of Dermatology"],"published-print":{"date-parts":[[2026,4]]},"DOI":"10.1016\/j.jaad.2025.12.024","type":"journal-article","created":{"date-parts":[[2025,12,11]],"date-time":"2025-12-11T16:43:47Z","timestamp":1765471427000},"page":"1167-1176","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":4,"title":["Bitopertin shows efficacy in patients with erythropoietic protoporphyria: Results from the randomized, double-blind, placebo-controlled AURORA trial"],"prefix":"10.1016","volume":"94","author":[{"given":"Amy K.","family":"Yeung","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Herbert L.","family":"Bonkovsky","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Manisha","family":"Balwani","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Karl E.","family":"Anderson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cynthia","family":"Levy","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Manish","family":"Thapar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bruce","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Melanie","family":"Chin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Will","family":"Savage","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Robert","family":"Desnick","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Siob\u00e1n","family":"Keel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"3","key":"10.1016\/j.jaad.2025.12.024_bib1","doi-asserted-by":"crossref","first-page":"298","DOI":"10.1016\/j.ymgme.2019.01.020","article-title":"Erythropoietic protoporphyria and X-linked protoporphyria: pathophysiology, genetics, clinical manifestations, and management","volume":"128","author":"Balwani","year":"2019","journal-title":"Mol Genet Metab"},{"issue":"1","key":"10.1016\/j.jaad.2025.12.024_bib2","doi-asserted-by":"crossref","first-page":"26","DOI":"10.2119\/molmed.2012.00340","volume":"19","author":"Balwani","year":"2013","journal-title":"Mol Med"},{"key":"10.1016\/j.jaad.2025.12.024_bib3","doi-asserted-by":"crossref","first-page":"321","DOI":"10.1146\/annurev-med-042921-123602","article-title":"Update on the porphyrias","volume":"75","author":"Dickey","year":"2024","journal-title":"Annu Rev Med"},{"issue":"1","key":"10.1016\/j.jaad.2025.12.024_bib4","doi-asserted-by":"crossref","first-page":"151","DOI":"10.3390\/diagnostics12010151","article-title":"Recognized and emerging features of erythropoietic and X-linked protoporphyria","volume":"12","author":"Di Pierro","year":"2022","journal-title":"Diagnostics (Basel)"},{"issue":"24","key":"10.1016\/j.jaad.2025.12.024_bib5","first-page":"2921","article-title":"How I treat erythropoietic protoporphyria and X-linked protoporphyria","volume":"141","author":"Leaf","year":"2023","journal-title":"Blood"},{"issue":"3","key":"10.1016\/j.jaad.2025.12.024_bib6","first-page":"99","article-title":"Erythropoietic protoporphyria patients in Slovenia","volume":"16","author":"Marko","year":"2007","journal-title":"Acta Dermatovenerol Alp Pannonica Adriat"},{"issue":"3","key":"10.1016\/j.jaad.2025.12.024_bib7","doi-asserted-by":"crossref","first-page":"278","DOI":"10.1111\/j.1365-2796.2010.02236.x","article-title":"Erythropoietic protoporphyria in Sweden: demographic, clinical, biochemical and genetic characteristics","volume":"269","author":"Wahlin","year":"2011","journal-title":"J Intern Med"},{"issue":"5","key":"10.1016\/j.jaad.2025.12.024_bib8","doi-asserted-by":"crossref","first-page":"849","DOI":"10.1007\/s10545-012-9544-4","article-title":"The incidence of inherited porphyrias in Europe","volume":"36","author":"Elder","year":"2013","journal-title":"J Inherit Metab Dis"},{"issue":"1","key":"10.1016\/j.jaad.2025.12.024_bib9","doi-asserted-by":"crossref","first-page":"140","DOI":"10.1038\/s41436-020-00951-8","article-title":"Evidence in the UK biobank for the underdiagnosis of erythropoietic protoporphyria","volume":"23","author":"Dickey","year":"2021","journal-title":"Genet Med"},{"issue":"1","key":"10.1016\/j.jaad.2025.12.024_bib10","doi-asserted-by":"crossref","first-page":"337","DOI":"10.1186\/s13023-024-03287-7","article-title":"Estimating carrier rates and prevalence of porphyria-associated gene variants in the Chinese population based on genetic databases","volume":"19","author":"Wang","year":"2024","journal-title":"Orphanet J Rare Dis"},{"issue":"3","key":"10.1016\/j.jaad.2025.12.024_bib11","doi-asserted-by":"crossref","first-page":"314","DOI":"10.1016\/j.ymgme.2019.01.023","article-title":"Psychosocial issues in erythropoietic protoporphyria - the perspective of parents, children, and young adults: a qualitative study","volume":"128","author":"Naik","year":"2019","journal-title":"Mol Genet Metab"},{"issue":"3","key":"10.1016\/j.jaad.2025.12.024_bib12","doi-asserted-by":"crossref","first-page":"574","DOI":"10.1111\/j.1365-2133.2006.07472.x","article-title":"Erythropoietic protoporphyria in the U.K.: clinical features and effect on quality of life","volume":"155","author":"Holme","year":"2006","journal-title":"Br J Dermatol"},{"issue":"1","key":"10.1016\/j.jaad.2025.12.024_bib13","first-page":"9","article-title":"Evaluating quality of life tools in North American patients with erythropoietic protoporphyria and X-linked protoporphyria","volume":"50","author":"Naik","year":"2019","journal-title":"JIMD Rep"},{"issue":"3","key":"10.1016\/j.jaad.2025.12.024_bib14","doi-asserted-by":"crossref","first-page":"433","DOI":"10.1007\/s10545-017-0017-7","article-title":"Disturbed iron metabolism in erythropoietic protoporphyria and association of GDF15 and gender with disease severity","volume":"40","author":"Barman-Aksoezen","year":"2017","journal-title":"J Inherit Metab Dis"},{"issue":"6","key":"10.1016\/j.jaad.2025.12.024_bib15","doi-asserted-by":"crossref","first-page":"1693","DOI":"10.1111\/bjd.15893","article-title":"Osteoporosis in patients with erythropoietic protoporphyria","volume":"177","author":"Biewenga","year":"2017","journal-title":"Br J Dermatol"},{"issue":"3","key":"10.1016\/j.jaad.2025.12.024_bib16","doi-asserted-by":"crossref","first-page":"731","DOI":"10.1097\/HEP.0000000000000546","article-title":"Evidence-based consensus guidelines for the diagnosis and management of protoporphyria-related liver dysfunction in erythropoietic protoporphyria and X-linked protoporphyria","volume":"79","author":"Levy","year":"2024","journal-title":"Hepatology"},{"issue":"1","key":"10.1016\/j.jaad.2025.12.024_bib20","doi-asserted-by":"crossref","first-page":"48","DOI":"10.1056\/NEJMoa1411481","article-title":"Afamelanotide for erythropoietic protoporphyria","volume":"373","author":"Langendonk","year":"2015","journal-title":"N Engl J Med"},{"issue":"1","key":"10.1016\/j.jaad.2025.12.024_bib21","doi-asserted-by":"crossref","first-page":"213","DOI":"10.1186\/s13023-020-01505-6","article-title":"Increased phototoxic burn tolerance time and quality of life in patients with erythropoietic protoporphyria treated with afamelanotide - a three years observational study","volume":"15","author":"Barman-Aks\u00f6zen","year":"2020","journal-title":"Orphanet J Rare Dis"},{"issue":"6","key":"10.1016\/j.jaad.2025.12.024_bib22","first-page":"689","article-title":"Afamelanotide for treatment of the protoporphyrias: impact on quality of life and laboratory parameters in a US cohort","volume":"14","author":"Leaf","year":"2024","journal-title":"Life (Basel)"},{"issue":"8","key":"10.1016\/j.jaad.2025.12.024_bib23","doi-asserted-by":"crossref","first-page":"1314","DOI":"10.3324\/haematol.2016.155671","article-title":"Extracellular glycine is necessary for optimal hemoglobinization of erythroid cells","volume":"102","author":"Garcia-Santos","year":"2017","journal-title":"Haematologica"},{"issue":"7-8","key":"10.1016\/j.jaad.2025.12.024_bib24","doi-asserted-by":"crossref","first-page":"477","DOI":"10.2533\/chimia.2018.477","article-title":"I (GlyT1) : a journey from lab to patient","volume":"72","author":"Pinard","year":"2018","journal-title":"Chimia (Aarau)"},{"issue":"10","key":"10.1016\/j.jaad.2025.12.024_bib25","doi-asserted-by":"crossref","first-page":"964","DOI":"10.1016\/j.exphem.2016.07.003","article-title":"Effects of GlyT1 inhibition on erythropoiesis and iron homeostasis in rats","volume":"44","author":"Winter","year":"2016","journal-title":"Exp Hematol"},{"issue":"8","key":"10.1016\/j.jaad.2025.12.024_bib26","doi-asserted-by":"crossref","first-page":"1221","DOI":"10.1016\/j.chembiol.2021.02.021","article-title":"Repurposing of glycine transport inhibitors for the treatment of erythropoietic protoporphyria","volume":"28","author":"Halloy","year":"2021","journal-title":"Cell Chem Biol"},{"issue":"18","key":"10.1016\/j.jaad.2025.12.024_bib27","doi-asserted-by":"crossref","DOI":"10.1172\/JCI181875","article-title":"The GLYT1 inhibitor bitopertin mitigates erythroid PPIX production and liver disease in erythroid protoporphyria","volume":"135","author":"Ducamp","year":"2025","journal-title":"J Clin Invest"},{"issue":"Suppl. 1","key":"10.1016\/j.jaad.2025.12.024_bib28","doi-asserted-by":"crossref","first-page":"1093","DOI":"10.1182\/blood-2024-203387","article-title":"Results from the BEACON trial: a Phase 2, randomized, open-label trial of bitopertin in erythropoietic protoporphyria","volume":"144","author":"Ross","year":"2024","journal-title":"Blood"},{"issue":"15","key":"10.1016\/j.jaad.2025.12.024_bib31","doi-asserted-by":"crossref","first-page":"1376","DOI":"10.1056\/NEJMoa2208754","article-title":"Dersimelagon in erythropoietic protoporphyrias","volume":"388","author":"Balwani","year":"2023","journal-title":"N Engl J Med"},{"issue":"1","key":"10.1016\/j.jaad.2025.12.024_bib32","doi-asserted-by":"crossref","first-page":"119","DOI":"10.1186\/s41687-023-00655-y","article-title":"Development and content validation of a sunlight exposure diary in patients with erythropoietic protoporphyria","volume":"7","author":"Mathias","year":"2023","journal-title":"J Patient Rep Outcomes"},{"issue":"6","key":"10.1016\/j.jaad.2025.12.024_bib33","doi-asserted-by":"crossref","first-page":"637","DOI":"10.1001\/jamapsychiatry.2014.163","article-title":"Effect of bitopertin, a glycine reuptake inhibitor, on negative symptoms of schizophrenia: a randomized, double-blind, proof-of-concept study","volume":"71","author":"Umbricht","year":"2014","journal-title":"JAMA Psychiatry"},{"key":"10.1016\/j.jaad.2025.12.024_bib34","doi-asserted-by":"crossref","first-page":"66","DOI":"10.1186\/s12888-016-0778-9","article-title":"A double-blind randomized study assessing safety and efficacy following one-year adjunctive treatment with bitopertin, a glycine reuptake inhibitor, in Japanese patients with schizophrenia","volume":"16","author":"Hirayasu","year":"2016","journal-title":"BMC Psychiatry"},{"issue":"13","key":"10.1016\/j.jaad.2025.12.024_bib35","doi-asserted-by":"crossref","first-page":"2429","DOI":"10.1007\/s00213-016-4317-7","article-title":"Effects of the glycine reuptake inhibitors bitopertin and RG7118 on glycine in cerebrospinal fluid: results of two proofs of mechanism studies in healthy volunteers","volume":"233","author":"Hofmann","year":"2016","journal-title":"Psychopharmacology"},{"issue":"2","key":"10.1016\/j.jaad.2025.12.024_bib36","doi-asserted-by":"crossref","first-page":"474","DOI":"10.1111\/bjh.17479","article-title":"Haematological effects of oral administration of bitopertin, a glycine transport inhibitor, in patients with non-transfusion-dependent \u03b2-thalassaemia","volume":"194","author":"Taher","year":"2021","journal-title":"Br J Haematol"},{"issue":"12","key":"10.1016\/j.jaad.2025.12.024_bib37","doi-asserted-by":"crossref","first-page":"1115","DOI":"10.1016\/S2215-0366(16)30344-3","volume":"3","author":"Bugarski-Kirola","year":"2016","journal-title":"Lancet Psychiatry"},{"issue":"4","key":"10.1016\/j.jaad.2025.12.024_bib38","doi-asserted-by":"crossref","first-page":"515","DOI":"10.1016\/j.dld.2021.08.007","article-title":"Liver involvement in patients with erythropoietic protoporphyria","volume":"54","author":"Wensink","year":"2022","journal-title":"Dig Liver Dis"},{"key":"10.1016\/j.jaad.2025.12.024_bib39","author":"Balwani"},{"issue":"3","key":"10.1016\/j.jaad.2025.12.024_bib40","doi-asserted-by":"crossref","DOI":"10.1097\/HC9.0000000000000657","article-title":"Liver involvement in a large cohort of patients with erythropoietic protoporphyria or X-linked protoporphyria","volume":"9","author":"Levy","year":"2025","journal-title":"Hepatol Commun"}],"container-title":["Journal of the American Academy of Dermatology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0190962225033687?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0190962225033687?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,10,13]],"date-time":"2026-10-13T08:24:15Z","timestamp":1791879855000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0190962225033687"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,4]]},"references-count":35,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2026,4]]}},"alternative-id":["S0190962225033687"],"URL":"https:\/\/doi.org\/10.1016\/j.jaad.2025.12.024","relation":{},"ISSN":["0190-9622"],"issn-type":[{"value":"0190-9622","type":"print"}],"subject":[],"published":{"date-parts":[[2026,4]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Bitopertin shows efficacy in patients with erythropoietic protoporphyria: Results from the randomized, double-blind, placebo-controlled AURORA trial","name":"articletitle","label":"Article Title"},{"value":"Journal of the American Academy of Dermatology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jaad.2025.12.024","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 The Author(s). Published by Elsevier Inc. on behalf of the American Academy of Dermatology, Inc.","name":"copyright","label":"Copyright"}]}}